Expression and regulation of AC133 and CD133 in glioblastoma

GLIA

Volumn 59, Issue 12, 2011, Pages 1974-1986

  Campos, Benito ^a   Zeng, Lingcheng ^a,b   Daotrong, Philip H ^a   Eckstein, Volker ^a   Unterberg, Andreas ^a   Mairbäurl, Heimo ^a   Herold Mende, Christel ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

CD133; Differentiation; Glioblastoma; Hypoxia

Indexed keywords

MESSENGER RNA; PROTEIN; PROTEIN AC133; PROTEIN CD133; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; GLIOBLASTOMA; GOLGI COMPLEX; OXYGEN TENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR DIFFERENTIATION; TUMOR XENOGRAFT;

ANTIGENS, CD; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLYCOPROTEINS; HUMANS; OXYGEN; PEPTIDES;

EID: 80053588700     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.21239     Document Type: Article

References (31)

1. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
2. Bauer N, Fonseca A, Florek M, Freund D, Jászai J, Bornhäuser M, Fargeas CA, Corbeil D. 2008. New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133). Cells Tissues Organs (Print) 188: 127-138.
3. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP. 2007. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67: 4010-4015.
4. Campos B, Herold-Mende CC. 2011. Insight into the complex regulation of CD133 in glioma. Int J Cancer 128: 501-10.
5. Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE, Ahmadi R, Lohr J, Dictus C, Gdynia G, Combs SE, Goidts V, Helmke BM, Eckstein V, Roth W, Beckhove P, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende C. 2010. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res 16: 2715-2728.
6. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, Modrusan Z, Nacu S, Guerrero S, Edgar KA, Wallin JJ, Lamszus K, Westphal M, Heim S, James CD, VandenBerg SR, Costello JF, Moorefield S, Cowdrey CJ, Prados M, Phillips HS. 2010. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 17: 362-375.
7. Chirasani SR, Sternjak A, Wend P, Momma S, Campos B, Herrmann IM, Graf D, Mitsiadis T, Herold-Mende C, Besser D, Synowitz M, Kettenmann H, Glass R. 2010. Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells. Brain 133: 1961-1972.
8. Corbeil D, Röper K, Hellwig A, Tavian M, Miraglia S, Watt SM, Simmons PJ, Peault B, Buck DW, Huttner WB. 2000. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 275: 5512-5520.
9. Corbeil D, Marzesco A, Wilsch-Bräuninger M, Huttner WB. 2010. The intriguing links between prominin-1 (CD133), cholesterol-based membrane microdomains, remodeling of apical plasma membrane protrusions, extracellular membrane particles, and (neuro)epithelial cell differentiation. FEBS Lett 584: 1659-1664.
10. Dictus C, Tronnier V, Unterberg A, Herold-Mende C. 2007. Comparative analysis of in vitro conditions for rat adult neural progenitor cells. J Neurosci Methods 161: 250-258.
11. Fargeas CA, Huttner WB, Corbeil D. 2007. Nomenclature of prominin-1 (CD133) splice variants-An update. Tissue Antigens 69: 602-606.
12. Fargeas CA, Joester A, Missol-Kolka E, Hellwig A, Huttner WB, Corbeil D. 2004. Identification of novel Prominin-1/CD133 splice variants with alternative C-termini and their expression in epididymis and testis. J Cell Sci 117: 4301-4311.
13. Fiegl M, Samudio I, Clise-Dwyer K, Burks JK, Mnjoyan Z, Andreeff M. 2009. CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood 113: 1504-1512.
14. Florek M, Haase M, Marzesco A, Freund D, Ehninger G, Huttner WB, Corbeil D. 2005. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 319: 15-26.
15. He H, Nilsson CL, Emmett MR, Marshall AG, Kroes RA, Moskal JR, Ji Y, Colman H, Priebe W, Lang FF, Conrad CA. 2010. Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation. J Proteome Res 9: 2098-2108.
16. Karcher S, Steiner H, Ahmadi R, Zoubaa S, Vasvari G, Bauer H, Unterberg A, Herold-Mende C. 2006. Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer 118: 2182-2189.
17. Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, Zeilstra J, Pals ST, Mehmet H, Stassi G, Medema JP. 2010. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 70: 719-729.
18. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK, Fine HA. 2006. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391-403.
19. Marzesco A, Janich P, Wilsch-Bräuninger M, Dubreuil V, Langenfeld K, Corbeil D, Huttner WB. 2005. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. J Cell Sci 118: 2849-2858.
20. McCord AM, Jamal M, Shankavaram UT, Shankavarum UT, Lang FF, Camphausen K, Tofilon PJ. 2009. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 7: 489-497.
21. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW. 1997. A novel five-transmembrane hematopoietic stem cell antigen: Isolation, characterization, and molecular cloning. Blood 90: 5013-5021.
22. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. 2003. Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828.
23. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. 2004. Identification of human brain tumour initiating cells. Nature 432: 396-401.
24. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, Pollack IF, Park DM. 2009. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28: 3949-3959.
25. Son MJ, Woolard K, Nam D, Lee J, Fine HA. 2009. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4: 440-452.
26. Taïeb N, Maresca M, Guo X, Garmy N, Fantini J, Yahi N. 2009. The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic ganglioside-binding motif. Cancer Lett 278: 164-173.
27. Wan F, Herold-Mende C, Campos B, Centner F, Dictus C, Becker N, Devens F, Mogler C, Felsberg J, Grabe N, Reifenberger G, Lichter P, Unterberg A, Bermejo JL, Ahmadi R. 2011. Association of stem cell-related markers and survival in astrocytic gliomas. Biomarkers 16: 136-143.
28. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW. 1997. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012.
29. Yu Y, Flint A, Dvorin EL, Bischoff J. 2002. AC133-2, a novel isoform of human AC133 stem cell antigen. J Biol Chem 277: 20711-20716.
30. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC. 2008. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14: 123-129.
31. Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z, Fang J. 2008. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res 27: 85